PHA Pharmagest Interactive SA

Equasens: General meeting - Results of the votes

Equasens: General meeting - Results of the votes

        

Villers-lès-Nancy, 1st July 2025 – 07:00 p.m. (CET)

PRESS RELEASE

RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED

TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING

OF 25 JUNE 2025

Number of shares comprising the share capital: 15,174,125

Number of shares with voting rights: 14,830,415

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,173,125

That means a quorum of 88.83% of the 14,830,415 shares with voting rights: the Ordinary Annual General Meeting was able to deliberate.

The Ordinary Annual General Meeting was held on Wednesday, 25 June 2025 at 5:30 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2024 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

Resolutions





Results of the votes





  • RESOLUTION ONE
Approval of the annual financial statements		Resolution adopted by:
  • 13,170,684 votes in favour
  • 0 vote against
  • 2,441 abstentions
  • RESOLUTION TWO
Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement		Resolution adopted by:
  • 12,831,312 votes in favour
  • 339,266 votes against
  • 2,547 abstentions
  • RESOLUTION THREE

    Approval of the consolidated financial statements
Resolution adopted by:
  • 13,170,684 votes in favour
  • 0 vote against
  • 2,441 abstentions
  • RESOLUTION FOUR
Appropriation of earnings, setting the dividend		Resolution adopted by:
  • 13,138,631 votes in favour
  • 34,494 votes against
  • 0 abstention
  • RESOLUTION FIVE
Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code		Resolution adopted by (*):
  • 13,101,211 votes in favour
  • 59,549 votes against
  • 12,365 abstentions
  • RESOLUTION SIX
Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2024 and mentioned in Article L. 22-10-9 of the French Commercial Code		Resolution adopted by:
  • 12,507,815 votes in favour
  • 665,242 votes against
  • 68 abstentions
  • RESOLUTION SEVEN
Approval of the components of compensation paid in 2024 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors		Resolution adopted by:
  • 13,115,547 votes in favour
  • 57,510 votes against
  • 68 abstentions
  • RESOLUTION EIGHT
Approval of the components of compensation paid in 2024 to Mr. Denis SUPPLISSON, Chief Executive Officer		Resolution adopted by:
  • 10,782,118 votes in favour
  • 2,390,939 votes against
  • 68 abstentions
  • RESOLUTION NINE
Approval of the components of compensation paid in 2024 to Mr. Grégoire DE ROTALIER, Deputy CEO		Resolution adopted by:
  • 10,782,118 votes in favour
  • 2,390,939 votes against
  • 68 abstentions
  • RESOLUTION TEN
Approval of the components of compensation paid in 2024 to Mr. Damien VALICON, Deputy CEO (non-Board member), as from 01/04/2024		Resolution adopted by:
  • 10,762,253 votes in favour
  • 2,410,804 votes against
  • 68 abstentions
  • RESOLUTION ELEVEN
Approval of the compensation policy for Mr. Thierry CHAPUSOT, Chairman of the Board of Directors, for 2025		Resolution adopted by:
  • 13,115,547 votes in favour
  • 57,510 votes against
  • 68 abstentions
  • RESOLUTION TWELVE
Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2025		Resolution adopted by:
  • 10,545,572 votes in favour
  • 2,454,875 votes against
  • 172,678 abstentions
  • RESOLUTION THIRTEEN
Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2025		Resolution adopted by:
  • 10,537,207 votes in favour
  • 2,463,240 votes against
  • 172,678 abstentions
  • RESOLUTION FOURTEEN
Approval of the compensation policy for Mr. Damien VALICON, Deputy Chief Executive Officer, for 2025		Resolution adopted by:
  • 10,537,207 votes in favour
  • 2,463,240 votes against
  • 172,678 abstentions
  • RESOLUTION FIFTEEN
Approval of the compensation policy for Directors		Resolution adopted by:
  • 13,127,845 votes in favour
  • 45,212 votes against
  • 68 abstentions
  • RESOLUTION SIXTEEN
Setting total annual compensation for Directors for 2025		Resolution adopted by:
  • 13,127,845 votes in favour
  • 45,212 votes against
  • 68 abstentions
  • RESOLUTION SEVENTEEN
Authorisation by the Company to repurchase its own shares		Resolution adopted by:
  • 11,297,178 votes in favour
  • 1,875,947 votes against
  • 0 abstention
  • RESOLUTION EIGHTEEN
Powers for formalities		Resolution adopted by:
  • 13,173,125 votes in favour
  • 0 vote against
  • 0 abstention

(*) After deduction of excluded voting rights

Upcoming financial communications

  • 31 July 2025: Q2 2025 revenue - After the close of trading
  • 26 September 2025: H1 2025 results: 26 September 2025

About

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.300 people across Europe.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid-caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group and on

CONTACTS

EQUASENS Group

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt

Tel: +33 (0)3 83 15 90 67 -

Financial communications agency:

FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 -

Attachment



EN
01/07/2025

Underlying

PHAPharmagest Interactive SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Mise à disposition du rapport financier semestriel 2025

EQUASENS : Mise à disposition du rapport financier semestriel 2025 Villers-lès-Nancy, le 30 septembre 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE EQUASENS annonce la publication de son rapport financier semestriel au 30 juin 2025 EQUASENS annonce que son rapport financier semestriel 2025 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) en date du 30 septembre 2025. Ce document est disponible sur le site Internet de l’AMF ainsi que sur celui d’EQUASENS : (Rubrique INVESTISSEURS / Section INFORMATION RÉGLEMENTÉE). Ce rapport financier semestriel est composé de la déclaration...

September 30, 2025 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Bilan S1 2025 contrat de liquidité

EQUASENS : Bilan S1 2025 contrat de liquidité Villers-lès-Nancy, le 29 septembre 2025 - 08h00 (CET) COMMUNIQUE DE PRESSE BILAN SEMESTRIEL S1-2025 DU CONTRAT DE LIQUIDITECONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT Au titre du contrat de liquidité confié par la société EQUASENS à la Société de Bourse Gilbert Dupont, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : Nombre d’actions : 3 540Solde en espèces : 55 775,07 €. Au cours du 1er semestre 2025, il a été négocié un total de : ACHAT59 121 titres2 428 700,43 €2 337 transactionsVENTE58 884 titr...

September 29, 2025 1 EN
Arnaud Riverain
  • Arnaud Riverain
PHA Pharmagest Inte...

EQUASENS (EQS) - Résultats S1 : Les investissements se poursuivent / A...

CA S1 116 M€ +7,4% ROC 21,1 M€ +1,2% / Marge opérationnelle courante 18,2% vs 19,3% au S1 2024 RN 18,1 M€ stable / Marge nette 15,6% vs 16,7% Dette financière nette -98,8 M€ / Gearing -41,3% vs -33,1% au 31/12/24 CA S2 attendu en progression de près de +10%

PHA PHARMAGEST INTERACTIVE SA
09/29/25 September 29, 2025 FR
 PRESS RELEASE
Free
PHA Pharmagest Inte...

Equasens: 2025 half-year results

Equasens: 2025 half-year results Villers-lès-Nancy, 26 September 2025 - 6:00 PM (CET) PRESS RELEASE 2025 half-year results Revenue: €116.0m (+7.4% reported and +6.4% like-for-like)Recurring EBITDA: €29.8m (+5.5%)Current Operating Profit €21.1m (+1.2%) Net Profit: €18.1m (+0.3%)Net Financial Surplus : €98.8m (+€19.2m / 31-12-2024) H1 2025 RESULTS(M€)2024Reported basis2025Reported basisChange / Reported basisRevenue108.0116.08.07.4%Recurring EBITDA28.229.81.55.5%Recurring EBITDA / Sales26.1%25.7%  Current operating profit20.921.10.21.2%COP / Sales19.3%18.2%  Net Profit18.118.10.00.3%Net ...

September 26, 2025 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Résultats semestriels 2025

EQUASENS : Résultats semestriels 2025 Villers-lès-Nancy, le 26 septembre 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Résultats semestriels 2025 Chiffre d'affaires : 116,0 M€ (+7,4% en publié et +6,4% en organique)EBITDA courant : 29,8 M€ (+5,5%)Résultat Opérationnel Courant : 21,1 M€ (+1,2%) Résultat Net : 18,1 M€ (+0,3%)Excédent financier net : 98,8 M€ (+19,2 M€ / 31-12-2024) RESULTATS S1 2025 (M€)Publié 2024Publié 2025Variation/publiéChiffre d'affaires108,0116,08,07,4%EBITDA courant28,229,81,55,5%EBITDA courant / CA26,1%25,7%  ROC20,921,10,21,2%ROC / CA19,3%18,2%  Résultat Net18,118,10,0...

September 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch